CTLA4 and Hepatic failure: Interestingly, CTLA-4 immunotherapeutic agents used in advanced cancer such as the anti-CTLA-4 monoclonal antibody ipilimumab, which augments T-cell activation and proliferation, have been associated with immune-mediated multi-organ damage, including several cases of hepatitis and liver failure [42].